Abstract:OBJECTIVE:To evaluate the safety and validity of neo-adjuvant chemoradiotherapy followed by surgery for locally advanced esophageal carcinoma.METHODS:Patients with IIB, III staged squamous cell carcinoma of thoracic esophagus were randomly allocated to either preoperative chemoradiotherapy followed by surgery (arm A) or surgery alone (arm B). In arm A, chemotherapy and radiotherapy were performed concurrently. Patients received two cycles of vinorelbine and cisplatin. Vinorelbine at 25 mg/m(2) per day was administered as a bolus infusion at d1, d8, d22 and d29. Cisplatin at 75 mg/m(2) was administered by an intravenous infusion at d1 and d22 (or 25 mg/m(2) days 1 - 4 and 22 - 25). A total radiotherapeutic dose of 40 Gy was delivered in 20 daily fractions of 2.0 Gy each (5 d/wk for 4 weeks). Three-incisioned esophagectomy was performed at Weeks 4 - 6 after chemoradiotherapy. Primary outcome was overall survival time. An interim analysis was performed in June 2011.RESULTS:From July 2007 to June 2011, 123 eligible patients were randomly assigned at 7 cooperative cancer centers (54 cases in arm A vs 69 cases in arm B). In arm A, the clinical response rate of chemoradiotherapy was 90.7%. All patients finished the preoperative chemoradiotherapy. Forty-nine cases continued to receive esophagectomy. The pathological complete response rate was 29.6%. The rate of R0 resection in arm A was significant higher than that in arm B(96.0% vs 85.5%, P = 0.015). The most common grade 3/4 toxicity of chemoradiotherapy was leukopenia occurring in 33 cases (61.1%). Vomiting and esophagitis were usually of Grade 1/2. No patient died or abandoned surgery because of chemoradiation toxicity. Between arms A and B, operative duration, blood loss, duration of chest tube drainage and length of postsurgical hospital stay were similar. The incidences of postoperative heart failure (2.0% vs 1.4%, P = 1.000), anastomotic leakage (8.2% vs 11.6%, P = 0.759) and hoarseness (6.1% vs 4.3%, P = 0.691) were not significantly different. The incidence of pulmonary infection in arm A was slightly higher than that in arm B (8.2% vs 1.4%, P = 0.094). No perioperative deaths occurred in either group. There were no significant differences in overall survivals at 1, 2 years between arms A and B (85.6%/75.5% vs 79.1%/66.1%, P = 0.207). The disease-free survivals at 1, 2 years in arm A were slightly higher than in arm B (86.6%/83.2% vs 70.9%/61.8%, P = 0.075).CONCLUSION:Neo-adjuvant chemoradiation followed by surgery may achieve a high clinical response rate and pathologic complete tumor regression rate. It significantly increases the R0 resection rate and down stage the esophageal cancer patients. But its ultimate efficacy awaits further follow-up studies.

Surgery with and Without Chemotherapy for Localized Carcinoma of Esophagus: a Meta-Analysis

[Meta-Analysis of Postoperative Adjuvant Chemotherapy for Localized Esophageal Carcinoma].

Adjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma: a Meta-Analysis of Randomized Controlled Trials and Nonrandomized Studies

Neoadjuvant Chemoradiotherapy for Resectable Esophagealcarcinoma: A Meta-Analysis

Survival Benefits from Neoadjuvant Chemotherapy in Esophageal Cancer:A Meta-Analysis

Efficacy of Postoperative Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis.

Comparison of esophageal cancer survival after neoadjuvant chemoradiotherapy plus surgery versus definitive chemoradiotherapy: A systematic review and meta-analysis

Meta-analysis of neoadjuvant chemotherapy for esophageal cancer

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for esophageal neoplasms: A systematic review and meta-analysis

Meta-analysis of Postoperative Efficacy in Patients Receiving Chemoradiotherapy Followed by Surgery for Resectable Esophageal Carcinoma

Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis.

[Short and long-term outcomes of neoadjuvant chemotherapy for locally advanced esophageal carcinoma].

[A Multi-Centered Randomized Controlled Study of Neo-Adjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of Esophagus: an Interim Analysis].

Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis

Chemoradiotherapy Followed by Surgery Could Improve the Efficacy of Treatments in Patients with Resectable Esophageal Carcinoma

[A Prospective Study of Combined Chemoradiotherapy Followed by Surgery in the Treatment of Esophageal Carcinoma].

Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis

Chemoradiotherapy with and Without Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.

[Neo-Adjuvant Chemoradiotherapy Followed by Surgery in Treatment of Advanced Esophageal Carcinoma].

Randomized controlled study on preoperative concurrent chemoradiotherapy versus surgery alone for esophageal squamous cell carcinoma

Effects of Neoadjuvant Chemotherapy Combined with Radiotherapy in Patients with Advanced Esophageal Carcinoma